Relay Technology Management Inc. and MedPanel, LLC are announced they have entered into a working partnership to offer a differentiated set of consultative services to biopharma business executives. Under this collaboration, MedPanel's primary research platform, Insights, which provides insight from clinicians and other healthcare decision makers, and Relay's Innovation Engine-powered solutions will be available on a combined basis in consulting projects. The result will be a powerful data and insights driven approach for strategic and tactical advice to life science industry clients. In addition to supporting business development professionals in biopharma with the BD Live! competitive intelligence suite, Relay Technology Management's consulting services and analytics offer decision support and real-time business intelligence to clinical, regulatory, and reimbursement teams across the industry. Ongoing engagements include clinical trial profiling & complexity, forecast modeling, decision support for portfolio optimization, business development and R&D opportunity identification and evaluation. Now, with the combination of these services, MedPanel and Relay will be able to seamlessly produce the most robust insights available to biopharma industry decision makers.

the addition of Dr. Marc Krellenstein as Chief Technology Officer. Dr. Krellenstein brings more than 20 years of industry leadership in search technology, text mining, and life science applications to Relay's growing technology platform. Dr. Krellenstein was the founder of Lucid Imagination and the former Chief Technology Officer and Vice President of Search and Discovery at Elsevier, and brings over twenty years of search tools and technology expertise to Relay. As CTO for Relay Technology Management, Krellenstein plans to expand product focus leading a growing team of top technologists to develop tools for the interpretation and utilization of data in the life science and healthcare arenas.

Relay Technology Management, Inc. announced the official launch of Business Development Live (BD Live!), a new unified, real-time data visualization, comparative asset analysis and tracking platform for the life sciences industry. Relay TM supports life science business development and licensing professionals validate opportunities and discover new assets. BD Live! provides access to a comprehensive information repository on biopharma assets and other relevant entities and utilizes cutting-edge data visualization technologies to create interactive dashboards that dramatically improve the user experience. Relay TM complements competitive intelligence by assessing the relative attractiveness of life science assets -- drugs, targets, researchers, and institutions, historically and in real time, from one screen. BD Live! is offered as a Software-as-a-Service subscription service with the following components: Comprehensive, real-time life sciences industry business intelligence: BD Live! aggregates and visualizes data from a comprehensive list of life science sources, including 27 million data points and growing representing a combination of scientific and business literature, technology transfer data, and clinical trial data. The platform harvests these data sources for daily updates and latest industry developments. Unified life sciences trend monitoring and comparative asset analysis: BD Live! offers real-time, analytical and customizable dashboards on drug profiles and targets, researchers and institutions based on their relative attractiveness within specific therapeutic areas. This enables life sciences professionals to rapidly compare related categories, such as emerging drug targets and approaches in a particular therapeutic area. BD Live! enables comparative asset analysis via an industry-first Relative Valuation Index (RVI). The Relay RVI accounts for the stage of asset development and factors in competitive environment, scientific evidence, investments, proof of mechanism, research momentum, FDA and transactional trends, among other variables. The Relay RVI is insulated from popular opinion to ensure robust and objective assessment of assets.